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A total of 16 premenopausal women with metastatic breast cancer (N¼13) or locally advanced primary breast cancer (N¼3) were
treated with a combination of a gonadotropin-releasing hormone agonist goserelin, and a selective aromatase inhibitor anastrozole.
All had previously been treated with goserelin and tamoxifen. In all, 12 patients (75%) achieved objective response or durable stable
disease at 6 months, with a median duration of remission of 17þ months (range 6–47 months). Four patients still have clinical
benefit. Introduction of goserelin and tamoxifen resulted in an 89% reduction in mean oestradiol levels (pretreatment vs 6
months¼224 vs 24pmoll
 1)( Po0.0001). Substitution of tamoxifen by anastrozole on progression resulted in a further 76% fall (to
6pmoll
 1 at 3 months) (Po0.0001). Treatment with goserelin and tamoxifen led to a 90% fall in the mean follicle-stimulating
hormone (Po0.001). This was reversed once therapy was changed to goserelin and anastrozole. A similar initial reduction was seen
in the mean luteinising hormone levels, but substitution of tamoxifen by anastrozole on progression resulted in no significant change.
Goserelin and tamoxifen did not lead to any significant change in testosterone and androstenedione levels. The combined use of
goserelin and anastrozole as second-line endocrine therapy produces a significant clinical response of worthwhile duration, with
demonstrable endocrine changes, in premenopausal women with advanced breast cancer, and offers them another therapeutic
option. Further studies involving more patients and longer follow-up are indicated.
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The combined use of a gonadotropin-releasing hormone (GnRH)
agonist (e.g. goserelin (Zoladex, AstraZeneca)) and tamoxifen in
premenopausal women with breast cancer is an established
therapeutic option – either using both agents together as initial
therapy or by adding tamoxifen following initial goserelin therapy
(Nicholson et al, 1985; Williams et al, 1986; Robertson et al, 1989a;
Jonat et al, 1995). Goserelin alone has been shown to produce
castrate levels of oestradiol (E2) (Williams et al, 1986) and
response rates similar to oophorectomy in premenopausal women
both in Phase II studies (Blamey et al, 1992) and in a randomised
study (Taylor et al, 1998). An early nonrandomised clinical study
suggested possible extension of the duration of response upon
addition of the antioestrogen tamoxifen to goserelin in premeno-
pausal patients with advanced breast cancer (Dixon et al, 1991).
More recently, a meta-analysis of four studies has revealed that
using the combination of goserelin and tamoxifen as initial therapy
produced a significantly longer time to first progression than using
goserelin alone (Klijn et al, 2001). The rationale for this therapy is
that, having effectively rendered the patient postmenopausal with
the use of goserelin, the effect of peripheral E2 production in
promoting hormone-sensitive breast cancer growth is inhibited by
tamoxifen, as in postmenopausal women. Indeed, the combination
of goserelin and tamoxifen has been shown to produce a
significantly lower concentration of follicle-stimulating hormone
(FSH) than goserelin alone, and a resultant (nonsignificant)
reduction in E2 (Robertson et al, 1989a).
Selective aromatase inhibitors (e.g. anastrozole (Arimidex,
AstraZeneca)) have now become the standard second-line endo-
crine therapy, after the failure of tamoxifen in postmenopausal
women with advanced breast cancer (Buzdar et al, 1998). They
now challenge tamoxifen as first-line endocrine therapy for
hormone-sensitive advanced breast cancer (Bonneterre et al,
2000; Nabholtz et al, 2000). Therefore, following the same logic
that has led to the combined use of goserelin and tamoxifen, we
now report clinical and endocrine data supporting the use of
goserelin combined with anastrozole for premenopausal women
with advanced breast cancer, who have progressed following
treatment with goserelin and tamoxifen.
PATIENTS AND METHODS
All premenopausal women who had been treated with goserelin
and anastrozole for advanced breast cancer in the Nottingham
Breast Unit were included in the study. A total of 16 such patients
with a mean age of 44 years (range 32–52 years) at the time of
commencing goserelin and anastrozole were identified in the
period 1997–2000. All of them had histologically proven breast Revised 9 September 2003; accepted 24 October 2003
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lcancer, and were treated in a dedicated Advanced Breast Cancer
Clinic. They had all previously been treated with goserelin and
tamoxifen, and had had a clinical benefit (see below). The median
duration of partial response (PR) on goserelin and tamoxifen was
52.5 months (range 27–59 months), and that of durable stable
disease (SD) was 23 months (range 10–84 months). The
indications for treatment were metastatic disease (n¼13) or
locally advanced primary breast cancer. In all, 14 patients had
oestrogen receptor (ER)-positive tumours. One had ER-negative
tumour and one unknown ER status. Progesterone receptor status
was not routinely done in this unit.
The treatment was changed to goserelin and anastrozole at the
time of disease progression. The sites of disease when goserelin
and anastrozole were commenced are summarised in Table 1.
Follow-up and assessment of therapeutic response
Patients were followed up at 6 weeks, 12 weeks and thereafter at 3-
monthly intervals. Clinical, radiological and biochemical (using
blood tumour markers - CA15.3, CEA and ESR (Robertson et al,
1991)) assessments were performed. Clinical and radiological
assessment of therapeutic response was carried out using criteria
laid down by the International Union Against Cancer (UICC)
(Hayward et al, 1977) while adhering to the British Breast Group
recommendations that the minimum duration of remission should
be 6 months (British Breast Group 1974). Objective response (OR)
was defined as either complete response (CR) or PR. Clinical
benefit was defined as OR or SD at 6 months (Howell et al, 1988;
Robertson et al, 1989b; Robertson et al, 1997).
The median duration of clinical benefit was 15 months (range:
6–32 months). The median time to progression was 10 months
(range: 2–16 months). Time to treatment failure was identical as
no patients discontinued therapy for any other reasons.
Therapy
All patients received goserelin 3.6mg. by subcutaneous injection
every 4 weeks along with anastrozole 1mg daily. Therapy was
continued until there was definite evidence of progressive disease
(PD) according to UICC criteria.
The duration of response was calculated from the time of
commencement of goserelin and anastrozole. Disease progression
was taken as the end point for this study.
Tumour markers
All patients had serum CA15.3 and CEA measured at routine clinic
visits to aid clinical management. Remaining serum was stored and
provided samples for retrospective hormone assays. Two patients
with unassessable disease (due to sclerotic bony metastases)
according to UICC criteria were assessed using tumour marker
measurements only (Cheung et al, 2001).
Hormone assays
Hormone assays were not performed routinely and have been
performed retrospectively on stored serum for this study. The
serum samples were stored at  201C. Samples were subsequently
retrieved and thawed. Standard assays for E2, FSH, luteinising
hormone (LH), testosterone, dehydroisoandrosterone (DHES) and
androstenedione were carried out in the respective Departments of
Clinical Chemistry at Nottingham City Hospital (E2) and the
Royal Marsden Hospital (LH, FSH, testosterone, DHES
and androstenedione). The E2 assay had a detection limit of
5pmoll
 1 and an intra-assay precision of 10% coefficient of
variation at 37pmoll
 1. Levels of the above hormones were
measured during treatment first with goserelin and tamoxifen
and subsequently with goserelin and anastrozole at pre-treatment,
3, 6 and 12 months and at subsequent visits. A total of 13
patients had a complete set of sequential serum samples available
for these assays.
Statistical method
Analyses were carried out using the standardised biomedical
computer programme SPSS for Windows (SPSS UK Ltd). The t-test
was used to compare pretreatment values with levels at 6 months –
the standard point taken for outcome. The data are displayed
graphically in Figures 1–6. The graph represents mean values and
the bars are standard errors of the mean. Statistically significant
difference was defined by Po0.05.
Table 1 Sites of disease for patients receiving goserelin and anastrozole
N
Locally advanced primary disease 3
Metastatic 13
Soft tissue 1
Bone7soft tissue 6
Pleura 1
Bone+Pleura 2
Visceral 3
Total 16
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Figure 1 Mean (standard error of the mean) serum oestradiol levels in
13 patients treated with goserelin plus tamoxifen, followed by goserelin
plus anastrozole.
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Figure 2 Mean (standard error of the mean) serum FSH levels in 13
patients treated with goserelin plus tamoxifen, followed by goserelin plus
anastrozole.
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lRESULTS
Clinical data
Details of the response data are tabulated (Table 2). In all, 12
patients showed clinical benefit. These included one PR and
nine SDs. A further two patients remained on goserelin and
anastrozole, with no evidence of PD beyond 6 months with
decreasing blood tumour markers (i.e. having a biochemical
response), although the disease was unassessable by UICC criteria.
The clinical benefit rate (ORþSDþbiochemical response) at 6
months was therefore 75%.
Four patients progressed before 6 months (median¼2.5
months). Two had pre-existing liver metastases; the third had
local and pleural disease and the fourth patient had a locally
advanced primary tumour.
For the 12 patients receiving goserelin and anastrozole
for at least 6 months, the median duration of response
was 17 months (range 6–47 months). Among these 12 patients,
eight have progressed, while four continue to have clinical
benefit.
The treatment was well tolerated, with no significant
symptoms reported to either the clinician or the specialist
breast care nurse assessing the patients. No patient dis-
continued therapy because of side effects of goserelin and
anastrozole.
Endocrine data
Figures 1–6 show the mean serum hormone levels from 13
patients for whom complete sets of sequential serum samples were
obtainable. Changes in the first 12 months on goserelin and
tamoxifen are shown, followed by those in the first 12 months on
goserelin and anastrozole after progression.
Introduction of goserelin and tamoxifen led to an 89% reduction
in E2 levels compared to pretreatment – mean concentration
pretreatment vs 6 months being 224 and 24pmoll
 1, respectively
(Po0.0001). Substitution of tamoxifen by anastrozole on progres-
sion resulted in a further 76% fall in serum E2 levels – mean
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Figure 3 Mean (standard error of the mean) serum LH levels in 13
patients treated with goserelin plus tamoxifen, followed by goserelin plus
anastrozole.
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Figure 4 Mean (standard error of the mean) serum testosterone levels
in 13 patients treated with goserelin plus tamoxifen, followed by goserelin
plus anastrozole.
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Figure 5 Mean (standard error of the mean) serum DHES levels in 13
patients treated with goserelin plus tamoxifen, followed by goserelin plus
anastrozole.
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Figure 6 Mean (standard error of the mean) serum androstenedione
levels in 13 patients treated with goserelin plus tamoxifen, followed by
goserelin plus anastrozole.
Table 2 Response and duration of therapy on goserelin and anastrozole
UICC response at
6 months No. of patients
Duration of therapy
(months)
PR 1 31*
SD 9 6, 11, 12, 16, 17, 17, 19*, 31, 47*
P D 4 1 ,2 ,3 ,4
U/A 2 15*, 21
*Patients who have not yet progressed on goserelin and anastrozole. U/A,
unassessable by UICC criteria.
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5pmoll
 1, respectively (Po0.0001). These figures were in agree-
ment with laboratory reference intervals at our hospital: pre-
menopausal levels 4200pmoll
 1 and postmenopausal levels
o110pmoll
 1.
Serum FSH levels also showed a significant change (Figure 2).
The mean pretreatment level was 10.1pmoll
 1. Introduction of
goserelin and tamoxifen led to a 90% fall to 1.0pmoll
 1 at 6
months (Po0.001). Once the therapy was changed to goserelin and
anastrozole, there was a significant rise in the mean FSH level to
7.8pmoll
 1 at 12 months (Po0.0001).
Introduction of goserelin and tamoxifen resulted in an 89%
reduction in mean LH levels (pretreatment vs 6 months¼19.9 vs
0.3pmoll
 1)( P¼0.01) (Figure 3). Substitution of tamoxifen by
anastrozole on progression produced no significant change in LH
levels.
Treatment with goserelin and tamoxifen resulted in no overall
change in testosterone levels (Figure 4). Substitution of tamoxifen
by anastrozole on progression led to a significant fall in mean
testosterone levels from 1.06 to 0.85pmoll
 1 (Po0.05). There was
a clear falling trend with goserelin and anastrozole, which had not
been present during treatment with goserelin and tamoxifen.
There was no significant change in DHES levels throughout the
two treatments (Figure 5).
Introduction of goserelin and tamoxifen resulted in a 31%
reduction in mean androstenedione levels (pretreatment versus 6
months¼6.1 vs 4.2pmoll
 1), but the fall was statistically
insignificant. Substitution of tamoxifen by anastrozole on progres-
sion produced a further 18% fall from 4.2 to 3.4pmoll
 1 (Po0.02).
DISCUSSION
In postmenopausal women with oestrogen-dependent breast
carcinoma, oestrogen is suppressed both at the receptor level
and by reducing circulating levels. Agents are used sequentially,
for example, Tamoxifen followed by aromatase inhibitors
such as anastrozole. Sequential hormone treatments for premeno-
pausal patients with advanced breast cancer are less established.
Ovarian ablation (e.g. oophorectomy or irradiation) has been
used for over 100 years since Beatson first reported response to
surgical oophorectomy in a patient with advanced breast
cancer (Beatson 1896). Much more recently, ovarian suppression
with GnRH agonist (e.g. goserelin) has been reported to
produce response rates similar to ovarian ablation both in
phase II studies (Blamey et al, 1992) and in a multicentre
randomised trial (Taylor et al, 1998). Furthermore treatment with
goserelin has been shown to result in castrate levels of E2
(Nicholson et al, 1985).
Tamoxifen is a well-established first-line endocrine therapy in
postmenopausal women with advanced breast cancer. Megestrol
acetate was the standard second-line endocrine agent after failing
tamoxifen, and has now been replaced by selective aromatase
inhibitors (e.g. anastrozole) (Buzdar et al, 1998). Recent data have
shown at least equivalent effects between tamoxifen and anastro-
zole as first-line endocrine therapy (Bonneterre et al, 2000;
Nabholtz et al, 2000). The time to progression was found to be
significantly longer in patients treated with anastrozole than with
tamoxifen in some of these randomised trials (Nabholtz et al, 2000;
Milla-Santos et al, 2003). Similar results were also seen with other
third-generation aromatase inhibitors such as letrozole (Mour-
idsen et al, 2001).
The induction of menopause using goserelin and its combina-
tion with tamoxifen is a rational extension for treating premeno-
pausal women with advanced breast cancer (Klijn et al, 2001). It
has been demonstrated to produce a significant OR rate of
worthwhile duration. Further extension of treatment regimes in
premenopausal women has led to the substitution of tamoxifen by
a selective aromatase inhibitor (e.g. anastrozole) on progression of
disease, just as in postmenopausal women.
Clinical response
The results reported here show that further significant remission
of worthwhile duration can be achieved using anastrozole in
combination with goserelin, after tamoxifen has ceased to be
effective. Clinical benefit was achieved in 12 out of 16 patients
(75%) at 6 months, with a median duration of therapy of 17þ
months. One of the four patients who progressed before 6 months
was in fact offered chemotherapy as the treatment of choice for her
liver metastases, but she refused and requested to be put on
endocrine therapy. It would therefore appear that the response rate
might be higher if only patients who had endocrine therapy as the
appropriate treatment option were included. Although the number
of patients in this series is small, the response rate has far exceeded
that of traditional second-line endocrine therapy for advanced
breast cancer in postmenopausal women (our previous study has
shown an ORþSD rate of 53% using megestrol acetate, with a
median duration of response of 15 months (Cheung et al, 1997)).
The result in the present study represents a significant extension of
disease control after progression on prior goserelin and tamoxifen,
and compares favourably to the use of anastrozole in postmeno-
pausal women (Wiseman and Adkins, 1998).
Patients in this study all had previously responded to goserelin
and tamoxifen with a clinical benefit. However, it should be noted
that the type of response is lower than that achieved with goserelin
and tamoxifen. In the 16 patients studied, treatment with goserelin
and tamoxifen resulted in one CR, five PRs and 10 SDs at 6
months. At progression, when tamoxifen was substituted by
anastrozole, only one patient achieved a PR, with nine having SD.
There were two patients with non-PD, as assessed by tumour
marker response. There were no patients who achieved a CR. This
finding is expected, as it is well known that response rates fall with
each sequential endocrine manoeuvre, although the durable SD
rate remains high. It must be noted that, despite a lower CR/PR
rate, the clinical benefit rate (CR/PR/SD) was high, and it has been
established that patients who have achieved SD for 6 months on an
endocrine therapy have survival equivalent to those with CR/PR
(Howell et al, 1988; Robertson et al, 1997, 1989b). A similar effect
was also seen in the duration of response, which again became
shortened with second-line endocrine therapy using goserelin and
anastrozole.
Endocrine response
The results for the different hormones assayed will be considered
in turn. Oestradiol levels shown in Figure 1 confirm that castrate
levels can be achieved with the introduction of goserelin, as
previously shown (Robertson et al, 1989a). There was, however, a
further 76% fall (Po0.0001) in E2 levels when tamoxifen was
substituted by anastrozole (from 23.6 to 6.96pmoll
 1). This was
associated with a good clinical response, as shown above. There
were no peaks of E2 activity noted in any of the serum samples.
Follicle-stimulating hormone levels were initially suppressed by
treatment with goserelin and tamoxifen. Again, this is consistent
with results previously seen (Robertson et al, 1989a). However,
substitution of tamoxifen by anastrozole led to a partial loss of this
suppression, with FSH levels rising towards pretreatment values.
This may be due to the effect of a negative feedback as a result of
further reduction in E2 levels upon the introduction of an
aromatase inhibitor. It may also be a rebound phenomenon from
coming off tamoxifen.
Luteinising hormone levels were suppressed, as would be
expected by constant administration of a GnRH analogue. There
was no significant change in LH levels on goserelin plus
anastrozole.
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and tamoxifen. Substitution of tamoxifen by anastrozole produced
a 20% fall in testosterone levels (Po0.05). Androstenedione levels
were also unchanged by treatment with goserelin and tamoxifen.
Again, as with testosterone, there was a significant but small fall in
hormone levels when tamoxifen was substituted by anastrozole –
18% (Po0.02). The levels of DHES were unaltered by treatment
with either combination. It would appear that these substrates for
aromatase (i.e. the precursors from which E2 is converted) do not
increase with a blockade of the conversion system by the third-
generation aromatase inhibitors (e.g. anastrozole).
This study has a relatively small number of patients and short
overall follow-up to date. Nevertheless, it is the first study
reporting on the clinical and endocrine effects of the combined
use of goserelin and anastrozole as a second-line endocrine
therapy for premenopausal women with advanced breast cancer.
The endocrine changes are more interesting by having similar data
from the same patients, while they received goserelin and
tamoxifen as first-line endocrine therapy. The combination of
goserelin and anastrozole produces a significant clinical benefit
rate, which is also of worthwhile duration in this group of patients.
Such combination therefore offers a clinically valuable therapeutic
option. Further studies involving a larger number of patients and
longer duration of follow-up are indicated. Such evaluation now
appears to be of paramount importance, as the selective aromatase
inhibitors (eg anastrozole) have recently been shown to be the
preferred first-line endocrine therapy to tamoxifen in postmeno-
pausal women with advanced breast cancer.
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